Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA approves Keveyis for primary hyperkalemic and hypokalemic periodic paralysis

Aug. 11, 2015

Sanofi files application for alirocumab approval in Japan

Aug. 11, 2015

Merck & Co. divulges MGAT2 inhibitors

Aug. 11, 2015

Daiichi Sankyo discloses LCAT activators

Aug. 11, 2015

Sanofi and Evotec to collaborate on beta-cell-targeting therapies for diabetes

Aug. 10, 2015

Antisense therapy proved effective in reducing triglyceride levels

Aug. 10, 2015

Kwang Dong licenses South Korean rights to Contrave

Aug. 10, 2015

Dicerna's DCR-PH1 receives orphan drug designation from the EMA

Aug. 7, 2015

Vtesse reports preliminary data from ongoing phase I study of VTS-270

Aug. 7, 2015

Ultragenyx begins phase II study of recombinant human beta-glucuronidase

Aug. 7, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 6, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...